Oncology and Advanced Solid Tumors
Apollomics Inc. focuses on advanced malignancies with an emphasis on solid tumors that show MET dysregulation, including cancers marked by MET amplification, MET fusion, and MET overexpression.
- Pan-cancer solid tumor research
- MET-altered malignancies
- Wild-type MET with HGF overexpression
The sponsor’s research activity centers on tumor types where MET pathway abnormalities are clinically relevant.
Non-Small Cell Lung Cancer
A major area of interest is non-small cell lung cancer with MET exon 14 skipping mutations and MET amplification, alongside disease settings involving acquired resistance after prior EGFR inhibitor treatment.
- NSCLC with MET exon 14 skipping
- NSCLC with MET amplification
- EGFR-mutant NSCLC with MET-mediated resistance
This area reflects a therapeutic focus on lung cancers driven by MET signaling alterations.
Central Nervous System Tumors
The sponsor also includes primary CNS tumors among its research interests, particularly those harboring MET alterations.
- Primary central nervous system tumors
- MET-altered CNS disease
This extends its oncology portfolio into brain and nervous system malignancies with actionable molecular targets.
Targeted Therapy and Molecular Oncology
Apollomics Inc. is engaged in research around targeted anticancer therapy for tumors defined by specific genomic alterations, with a clear emphasis on MET-driven pathways and related molecular biomarkers.
- MET pathway targeting
- Biomarker-defined cancers
- Resistance-associated tumor biology
Its clinical interests include cancers selected by molecular profiling rather than broad tumor histology alone.
